Summan A late phase I1 study of a new camptothecin analogue. inrnotecan hydrochloride (CPT-l1). was conducted to evaluate the anti-tumour effect and toxicity in patients with refractory leukaemia and lymphoma including adult T-cell leukaemia (ATL)-lymphoma. in a multi-institutional cooperative study. All the patients with ATL had been previously treated with various conventional combination chemotherapies and were refractonr to these therapies or had relapsed. CPT-1 1 was administered at a dose of 40 mg m-day -' for three consecutive days repeated weekly until eVidence of disease progression. One complete remission and four partial remissions were achieved in 13 assessable patients with ATL. The median total dose to achieve remission was 240 mg m and the median duration of response was 31 days. The major toxicities were leucopenia (83%). diarrhoea (62%) and nausea vomiting (69%). These were relatively severe. but they were generally tolerable and reversible. However. one patient died probably as a result of this therapy. No effective chemotherapy for adult T-cell leukaemia-lymphoma has yet been established, and the prognosis for patients with this disease is very poor. Our results suggest that CPT-l1 may be a promising agent for this disease. Further combination therapy with CPT-11 is needed to improve the therapy for ATL.
The prognosis of adult T-cell leukaemia-lymphoma (ATL) is generally very poor (Shimoyama et al., 1988a (Shimoyama et al., . 1991 . and the median survival times (MSTs) for the acute, lymphoma and chronic types are 5.4, 10.2 and 24.3 months respectively (Shimoyama et al., 1991) . Chemotherapy for ATL has been largely unsuccessful because of tumour resistance, and it was recently reported that ATL cells frequently express the MDR-1 gene product. a membrane P-glycoprotein., at the time of presentation (Kuwazuru et al., 1990) . Thus. a new agent having a different mechanism of action is needed, and activity in models of multidrug resistance may be relevant.
Irinotecan hydrochlonrde (CPT-ll) is a semisynthetic and water-soluble derivative of camptothecin, an anti-tumour alkaloid isolated from Camptotheca acuminata (Wall et al.. 1966) . This compound has displayed excellent in vitro and in vivo anti-tumour activity in a variety of preclinical studies (Kunimoto et al.. 1987 : Bissery et al.. 1991 . CPT-l acts through the inhibition of topoisomerase I (Kawato et al.. 1991 : Andoh. 1992 ). CPT-1 1 is reported to be effective against vincristine-and doxorubicin-resistant P388 leukaemia both in vitro and in vivo (Tsuruo et al.. 1988) , suggesting that it may be able to overcome multidrug resistance.
A late phase II study of CPT-11 was conducted in Japan to evaluate its anti-tumour effects and toxicity in patients with various types of leukaemia and lymphoma, including ATL (Tsuda et al.. 1992) . In the present report, the results were analysed with the focus on ATL, in order to determine whether CPT-I1 has any worthwhile activity against ATL.
Patients and methods

Patients
Patients were enrolled in this study if they fulfilled the following eligibility criteria: (1) histologically confirmed leukaemia or malignant lymphoma. (2) The toxicities caused by CPT-II therapy are listed in Table   III .
Myelosuppression was the most common toxicity observed: leucopenia was noted in 83%, anaemia in 67% and thrombocytopenia in 50%. Toxicity was generaly reversible, 2-3 weeks were required for recovery to the pretreatment level. Nausea and vomiting occurred in 69% and diarrhoea in 62%. All patients who experienced diarrhoea recovered. The median day of recovery from onset of diarrhoea was 4 days (range 1-34). Mild elevation of the level of glutamic oxaloacetic transaminase (GOT) and/or glutamic pyruvic transaminase (GPT) was seen in 15%. In addition, alopecia developed in 40%, but haemorrhagic cystitis was not observed. However, one patient (no. 4) died probably as a result of treatment for aspiration pneumonia caused by leucopenia.
The prognosis of adult patients with advanced peripheral T-cell lymphoma-leukaemia is generally poor, and ATL is the worst among this group of diseases (Shimoyama et al., 1988a) . Patients with ATL have been treated by various agents and schedules, such as VEPA (Shimoyama et al., 1988b) , CHOP (McKelvey et al.. 1976 ) and MACOP-B (Klimo et al.. 1985) . In addition, treatment with etoposide, interferon-a and interferon-y as single agents has been tried, but the survival benefit of any of these regimens remains uncertain (Shimoyama et al.. 1988a ). The MDR-1 gene or P-glycoprotein seems to be involved in the development of drug resistance in various tumours including ATL (Marie et al., 1991; Campos et al., 1992; Haber. 1992) . Thus, more effective agents and treatments for ATL are required.
The anti-tumour activity of CPT-I 1 is attributed to inhibition of topoisomerase I (Kawato et al., 1991; Andoh, 1992) .
In addition, it has been shown that there is no crossresistance between CPT-1 1 and adriamycin or vincristine both in animal tumour models and in vitro studies (Tsuruo et al.. 1988) . Phase II trials in various tumour types, including lung (Fukuoka et al., 1992a, b) , ovary, cervical (Umesaki, 1992) , colorectal cancer (Shimada et al., 1993) and haematological malignancies (Ohno et al.. 1990) . have been performed in Japan. and CPT-I 1 showed definite clinical response. The response rate of ATL patients in our study was 38% (5 13 The major side-effects were myelosuppression and gastrointestinal toxicities. Leucopenia was more severe than thrombocytopenia. as was observed in previous clinical studies. Diarrhoea was also severe, but reversible. It could generally be minimised by a standard dose of an anticholinergic agent. Treatment sometimes had to be postponed owing to leucopenia and diarrhoea, but in general treatment was repeated as planned. However. one patient died as a result of this treatment. The patient experienced grade 3 leucopenia and diarrhoea and a deterioration in general condition which caused an aspiration pneumonia. Thus, in regard to these side-effects, special care must be taken and adequate supportive therapy is needed.
According to a recent large-scale study, five factors are associated with a reduced survival in ATL, including poor performance status, high LDH level, age > 40 years. a greater number of lesions and hypercalcaemia . All patients enrolled in our study received various previous forms of chemotherapy and had several adverse prognostic factors (Table I ). This suggests that more satisfactory results may be achievable in untreated patients with better performance status.
In conclusion, our results show that CPT-l is clinically effective against ATL. Some cell lines resistant to CPT-ll have recently been established and have altered forms of CPT-l 1 (Kawato et al.. 1991; Andoh. 1992 ). An enhanced anti-tumour activity of CPT-11 in combination with other anticancer agents has been demonstrated both in vitro and in clinical studies (Kano et al.. 1992; Masuda et al.. 1993) . Accordingly. CPT-I I may be more effective when utilised in combination with other agents which have a different mode of action and different resistance mechanisms.
